C4 Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $12,006 | $3,039 | $3,261 | $11,072 |
Gross Profit | 9,961 | 1,012 | 1,570 | 9,077 |
EBITDA | -21,442 | -32,219 | -35,736 | -27,808 |
EBIT | -23,487 | -34,246 | -37,427 | -29,803 |
Net Income | -17,716 | -28,361 | -34,754 | -27,037 |
Net Change In Cash | 12,006 | 3,039 | 3,261 | 11,072 |
Free Cash Flow | -5,171 | -18,118 | -24,166 | -31,307 |
Cash | 73,114 | 89,659 | 126,590 | 60,971 |
Basic Shares | 68,810 | 68,432 | 51,216 | 49,212 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $20,756 | $31,096 | $45,785 | $33,195 |
Gross Profit | 13,019 | 23,524 | 42,878 | -44,273 |
EBITDA | -131,294 | -125,959 | -80,255 | -58,439 |
EBIT | -139,031 | -133,531 | -83,162 | -61,280 |
Net Income | -132,493 | -126,499 | -86,037 | -66,335 |
Net Change In Cash | 20,756 | 31,096 | 45,785 | 33,195 |
Cost of Revenue | -46,370 | -104,901 | 91,178 | |
Free Cash Flow | -108,546 | -111,435 | -88,242 | -67,899 |
Cash | 126,590 | 29,754 | 76,124 | 181,727 |
Basic Shares | 49,640 | 48,861 | 46,041 | 43,059 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.26 |
2024-03-31 | -$0.41 |
2023-12-31 | -$0.70 |
2023-09-30 | -$0.52 |
